CYTEIR THERAPEUTICS INC (CYT) Forecast, Price Target & Analyst Ratings

NASDAQ:CYT • US23284P1030

3.02 USD
-0.07 (-2.27%)
At close: Mar 15, 2024
3.1 USD
+0.08 (+2.65%)
After Hours: 3/15/2024, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CYTEIR THERAPEUTICS INC (CYT).

Forecast Snapshot

Consensus Price Target

Price Target
$3.06
+ 1.32% Upside

Next Earnings Forecast

Earnings Estimate
Release DateN/A
PeriodQ4 / 2023
EPS Estimate-$0.25
Revenue Estimate

ChartMill Buy Consensus

Rating
45.00%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
$3.06
Upside
+ 1.32%
From current price of $3.02 to mean target of $3.06, Based on 8 analyst forecasts
Low
$3.03
Median
$3.06
High
$3.15

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

8 analysts have analysed CYT and the average price target is 3.06 USD. This implies a price increase of 1.32% is expected in the next year compared to the current price of 3.02.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CYT Current Analyst RatingCYT Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

CYT Historical Analyst RatingsCYT Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
45.00%
CYT was analyzed by 8 analysts. The buy percentage consensus is at 45. So analysts seem to be rather negative about CYT.
In the previous month the buy percentage consensus was at a similar level.
CYT was analyzed by 8 analysts. More opinions would make the average more meaningful.
 → Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2024-01-05B of A SecuritiesDowngrade Neutral -> Underperform
2023-05-12WedbushReiterate Outperform -> Outperform
2023-02-03Morgan StanleyDowngrade Equal-Weight -> Underweight
2023-01-30B of A SecuritiesDowngrade Buy -> Neutral
2023-01-20JP MorganDowngrade Overweight -> Neutral
2022-09-09Morgan StanleyDowngrade Overweight -> Equal-Weight
2022-02-07Northland Capital MarketsInitiate Outperform
2021-07-13WedbushInitiate Outperform
2021-07-13JP MorganInitiate Overweight
2021-07-13B of A SecuritiesInitiate Buy
2021-07-13Morgan StanleyInitiate Overweight

Next Earnings Forecast Details

Next Earnings Details

Release DateN/A
PeriodQ4 / 2023
EPS Estimate-$0.25
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-1.00%
Number of Analysts3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

 → Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
CYT revenue by date.CYT revenue by date.
10KN/A
-100.00%		60.704M118.54M
95.28%		181.6M
53.20%		240.28M
32.31%
EBITDA
YoY % growth
CYT ebitda by date.CYT ebitda by date.
-15.89MN/A
-29.58%		-14.438M
-102.91%		-16.315M
-13.69%		-43.028M
9.41%		5.937M
113.80%		-49.425M
-932.50%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
CYT ebit by date.CYT ebit by date.
-16.11MN/A
-29.98%		-26.266M
-101.81%		-51.391M
-13.98%		-43.787M
9.10%		5.06M
111.56%		-55.947M
-1,205.68%		-67.083M
-19.90%		-26.509M
60.48%		8.689M
132.78%		48.411M
457.15%		16.127M
-66.69%
Operating Margin
CYT operating margin by date.CYT operating margin by date.
-161,100.00%N/AN/AN/AN/AN/AN/AN/A-43.67%7.33%26.66%6.71%
EPS
YoY % growth
CYT eps by date.CYT eps by date.
N/AN/A-2.11-1.41
38.30%		-1.09
16.09%		-0.88
19.44%		-0.87
1.15%		-0.79
9.30%		-0.15
80.77%		0.26
273.33%		0.71
169.23%		0.45
-35.71%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.25
-1.00%		-0.25
27.86%		-0.26
-9.42%		-0.27
-8.00%		-0.28
-12.00%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		12.09M
228.89%		N/AN/AN/AN/A
EBIT
Q2Q % growth		12.09M
220.30%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CYT Yearly Revenue VS EstimatesCYT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2028 2029 2030 50M 100M 150M 200M
CYT Yearly EPS VS EstimatesCYT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1 -1.5 -2

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
10.02%
EPS Next 5 Year
13.50%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
1.26%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CYTEIR THERAPEUTICS INC / CYT Forecast FAQ

What do analysts expect the price target to be for CYTEIR THERAPEUTICS INC (CYT)?

8 analysts have analysed CYT and the average price target is 3.06 USD. This implies a price increase of 1.32% is expected in the next year compared to the current price of 3.02.


What are the consensus estimates for CYTEIR THERAPEUTICS INC (CYT) next earnings?

The consensus EPS estimate for the next earnings of CYTEIR THERAPEUTICS INC (CYT) is -0.25 USD and the consensus revenue estimate is 0 USD.


What is the consensus rating for CYTEIR THERAPEUTICS INC (CYT) stock?

The consensus rating for CYTEIR THERAPEUTICS INC (CYT) is 45 / 100 . This indicates that analysts generally have a neutral outlook on the stock.